US keeps India on IPR watch list but expectations run high
This article was originally published in Scrip
India stays a "priority watch list" partner nation that presents the most significant intellectual property rights (IPR)-related concerns for the US but was spared another immediate out-of-cycle review (OCR) in view of steps initiated by the Indian government indicating that it is "engaged and examining" key IPR issues.
You may also be interested in...
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.